氩离子凝固术联合质子泵抑制剂治疗Barrett食管近期疗效分析

目的 探讨氩离子凝固术（APC）联合质子泵抑制剂（PPI）治疗Barrett食管的安全性及其临床疗效.方法 选择经胃镜和病理检查确诊的Barrett食管患者86例,对其行氩离子凝固术联合质子泵抑制剂治疗,质子泵抑制剂每次20 mg,每日2次,共用8周.分别于术后1、6、12个月复查胃镜,评价其临床疗效和不良反应.结果 所有患者均完成治疗,其中首次治疗并清除全部病灶80例,经2次治疗清除全部病灶6例.1年内复发患者6例.治疗有效率为93.0％,1年内复发率为6.9％.结论 内镜下氩离子凝固术联合质子泵抑制剂治疗Barrett食管安全可靠,近期临床疗效较好.     

胃镜下氩离子凝固术治疗Barrett食管的临床研究

目的探讨内镜下氩离子凝固术治疗Barrett食管的临床疗效。方法选择我院2006年3月-2007年4月经内镜检查及病理组织学检查诊断的Barrett食管患者87例,在内镜下行氩离子凝固术治疗,所有病例治疗后3个月及6个月时复查内镜以及病理组织学检查。结果87例Barrett食管患者3个月复查时78例（89.7％）胃镜下未见复发,9例（10.3％）由于BE黏膜长度较长,在原来部位有散在Barrett食管上皮残留,行第二次氩离子凝固术治疗,6个月复查胃镜及病理组织学检查,全部患者均未见Barrett黏膜复发。结论氩离子凝固术是经内镜非接触性治疗Barrett食管的新方法,操作方便,短期疗效较好。     

氩离子凝固术加抑酸逆转Barrett's食管上皮的临床研究

目的观察氩离子凝固术(APC)加抑酸治疗对Barrett’s食管上皮的逆转作用。方法对45例以内镜和病理确诊的Barrett’s食管病人,随机分为治疗组与对照组,治疗组采用氩离子凝固加质子泵抑制剂(APC)组,对照组采用传统质子泵抑制剂治疗(PPI组)。于治疗后第3个月和第6个月进行内镜及病理复查,观察2组Barrett’s食管上皮逆转情况。结果APC组23例Barrett’s食管上皮逆转总有效率在第3、6个月时分别为69.6%和82.6%,而对照组(PPI组)分别为9.5%和22.2%。无出血、穿孔等严重并发症。结论氩离子凝固术结合抑酸治疗能有效逆转Barrett’s食管上皮,大多数患者出现鳞状上皮再生,但不排除在新生的鳞状上皮下有残留的肠上皮化生及复发的可能,需长期随诊。     

内镜下氩离子凝固术治疗Barrett食管疗效分析

目的 探讨内镜下氩离子凝固术(APC)治疗Barrett食管(BE)的临床疗效.方法 选择经增强放大内镜及病理组织检查确诊的56例Barrett食管患者,进行45 W流量1.5 L/min的APC治疗,术后予以质子泵抑制剂辅助治疗.并于术后第6、12个月进行增强放大内镜随访.结果 56例BE经APC治疗均完全消除BE上皮.治疗次数共72次,平均每例1.3次,1次42例(75%),2次12例(21.4%),3次2例(3.6 %).56例患者中51例进行了临床随访,48例完成2次随访,3例完成1次随访.51例随访中4例复发(7.8%),且均为LSBE,12个月随访治疗总有效率94.1%.结论 氩离子凝固术治疗Barrett食管是一种安全、有效、简便的方法.     

氩离子凝固术联合埃索美拉唑治疗Barrett食管100例临床分析

目的 探讨内镜下氢离子凝固术联合抑酸治疗对Barrett食管的临床疗效.方法 100例Barett食管患者采用氩离子凝固术治疗,术后予埃索美拉唑维持治疗.100例均完成治疗,对照组50例仅予埃索美拉唑治疗,术后进行内镜、病理随访6个月.结果 100例均完成治疗,其中需要1次治疗者90例,2次者10例.总有效率90%,优于对照组这80.2%.术后出现30例胸骨后疼痛,2例黏膜下气肿,1例吞咽不畅.结论 氩离子凝固术联合埃索美拉唑治疗治疗Barrett食管操作简便,近期疗效显著,并发症少.但有一定比例的复发和残留.     

氩离子凝固术联合埃索美拉唑治疗Barret食管100例临床分析

目的探讨内镜下氢离子凝固术联合抑酸治疗对Barrett食管的临床疗效。方法 100例Barett食管患者采用氩离子凝固术治疗,术后予埃索美拉唑维持治疗。100例均完成治疗,对照组50例仅予埃索美拉唑治疗,术后进行内镜、病理随访6个月。结果 100例均完成治疗,其中需要1次治疗者90例,2次者10例。总有效率90%,优于对照组这80.2%。术后出现30例胸骨后疼痛,2例黏膜下气肿,1例吞咽不畅。结论氩离子凝固术联合埃索美拉唑治疗治疗Barrett食管操作简便,近期疗效显著,并发症少。但有一定比例的复发和残留。     

染色放大内镜下氩气凝固治疗Barrett食管的疗效观察

目的：评价染色放大内镜下氩离子凝固术对Barrett食管的治疗作用。方法：对经放大染色内镜观察并经病理证实为Barrett食管的28例患者,行氩气凝固治疗48次,分别于术后半年、1年、2年进行染色放大内镜及病理复查,评价其治疗效果和不良反应。结果：所有患者均安全完成治疗并全部清除病灶,治疗总有效率100％;4例术后出现胸痛,经加强抑酸治疗后缓解;半年后复查未见复发,1年后复查有2例复发,2年后复查有4例复发,总复发率21．4％。结论：氩气凝固治疗术能有效治疗Barrett食管,方法简便易行,安全、有效,但有一定比例的复发,应定期复查。     

内镜APC治疗短段Barrett食管近期临床观察

Barrett食管（BE）为公认的食管癌前病变,有发展成为食管腺癌的风险。内镜治疗是目前临床上BE的主要治疗手段。目的：探讨内镜氩离子凝固术（APC）治疗短段BE的近期疗效和安全性。方法：选取经内镜和病理检查确诊,于2010年6月一2011年12月在嵊泗县人民医院接受内镜30WAPC治疗辅以雷贝拉唑口服维持的短段BE患者,对其病史资料进行回顾性分析。结果：共12例短段BE患者纳入研究,11例完成内镜随访。9例患者首次APC治疗即完全清除病灶,2例患者接受2次APC治疗,按意向治疗分析总有效率为91．7％,无严重并发症发生。病灶完全清除后6个月、12个月内镜随访均未见复发。结论：内镜APC联合质子泵抑制剂维持治疗对清除短段BE近期疗效显著、安全,易于在基层医院开展。     

氩离子凝固术联合质子泵抑制剂治疗Barrett食管的长期疗效分析

目的评估氩离子凝固术（APC）联合质子泵抑制剂（PPI）逆转Barrett食管（BE）的长期疗效。方法对2004年至2007年经胃镜检查并经病理证实的36例BE患者采用APC联合PPI（每天20mg）治疗,分别于治疗后第1、6、12个月复查,以后每年1次内镜随访。结果36例患者共行48次APC治疗,平均1．33次／例,经治疗后均获得BE完全逆转。随访14～51个月,中位时间36个月,BE总复发率为16．7％（6／36）,1年复发率为2．8％（1／36）,2年复发率为11．1％（4／36）。Logistic回归分析显示,2年复发率和总复发率与APC治疗次数呈明显正相关（P值分别为0．004和0．007）。结论APC联合PPI治疗BE是一种安全、有效的方法,且长期疗效较好。     

窄带成像辅助氩等离子凝固术治疗Barrett食管的临床应用

目的 探讨内镜窄带成像技术（NBI）辅助氩等离子凝固术（APC）治疗Barrett食管的价值.方法 86例经内镜检查及病理诊断的Barrett食管,分别在普通模式及NBI模式下观察食管黏膜,以NBI放大观察病变的腺管开口形态及毛细血管结构形态.对所有NBI阳性部位均取活检,并以病理结果为标准,随机分为两组.Barrett食管的诊断时都用NBI内镜,治疗组42例,在NBI内镜辅助下进行APC治疗,内镜进入食管后,把APC探针经活检钳孔道伸出镜外1 cm,定位于需治疗黏膜1～2 cm处,以保证APC安全使用;对照组44例,在普通内镜下行APC治疗.于第3、6个月对两组进行内镜及病理随访.结果 两组治疗后第3、6个月从内镜、病理随访的有效率来看,治疗组与对照组的差异无统计学意义（P〉0.05）.结论 NBI辅助APC治疗Barrett食管能有效逆转Barrett上皮,并提高高级别上皮瘤样变的检出率,减少Barrett上皮逆转的治疗次数,且能部分缓解功能性胃肠病的症状,治疗安全.     

Barrett''s esophagus: combined treatment using argon plasma coagulation and laparoscopic antireflux surgery

The treatment of Barrett's esophagus is still controversial. Actually, the only method to prevent the development to cancer is endoscopic surveillance, which ensures good results in terms of long-term survival. An ideal treatment capable of destroying columnar metaplasia, followed by squamous epithelium regeneration could potentially result in a decrease of the incidence of adenocarcinoma. Recently most ablative techniques were used, such as photodynamic therapy, ablation therapy with Nd-YAG laser or argon plasma coagulation and endoscopic mucosal resection. We started a prospective study in January 1998, enrolling 94 patients affected by Barrett's esophagus and candidates for antireflux repair in order to assess the effectiveness and the results of endoscopic coagulation with argon plasma combined with surgery in the treatment of uncomplicated Barrett's esophagus. All patients underwent endoscopic treatment with argon plasma; we observed complete response in 68 patients (72.34%), 27 of them (39.7%) underwent antireflux surgery and the other 41 continued medical therapy. Post-operatively 19 patients (70%) underwent regular surveillance endoscopies and in two cases metaplasia recurred. The final objective of these combined treatments should be the complete eradication of metaplastic mucosa. Our experience was that argon plasma coagulation combined with antireflux surgery or proton pump inhibitor therapy gave satisfactory results, even if follow-up is too short to evaluate the potential evolution of metaplasia to cancer. For this reason, we recommend that this technique should be done only in specialized centres and that these patients continue their endoscopic surveillance program.     

内镜下氩离子凝固术联合奥美拉唑治疗Barrett食管76例临床及随访分析

目的探讨胃镜下氩离子凝固术联合奥美拉唑治疗Barrett食管的疗效。方法将胃镜检查并病理证实的76例Barrett食管（BE）患者随机分为对照组和治疗组,对照组36例给予口服奥美拉唑20 mg,1次/d;治疗组40例在胃镜下行氩离子凝固术（APC）,术后给予口服奥美拉唑20 mg,1次/d,对于一次治疗不能清除病灶的患者,4周后进行第二次清除,于术后3、6、12个月进行胃镜复查,对其疗效及并发症进行评估。结果对照组在治疗过程中,胃镜下BE长度和范围未见明显改变;至随访结束前,治疗组镜下保持完全清除的BE食管患者占APC治疗的72.5%,治疗组临床缓解率明显高于对照组（P〈0.05）。术后8例出现胸骨后不适,3例出现胸骨后疼痛,3例出现黏膜下气肿,2例出现低热。结论 Barrett食管的内镜下氩离子凝固术安全有效,有良好的临床应用前景。     

Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus

BACKGROUND: Endoscopic ablation of Barrett's esophagus has been described in which various thermocoagulation modalities are used in combination with a high dose of a proton pump inhibitor. No randomized comparison of ablation strategies has been published. METHODS: Referred patients were screened to identify those with Barrett's esophagus 2 to 7 cm in length, without high-grade dysplasia or cancer. Included patients received pantoprazole (40 mg twice a day), followed by randomization to treatment with argon plasma coagulation (APC) or multipolar electrocoagulation (MPEC). The primary outcome measure was the number of treatment sessions required for endoscopic ablation. RESULTS: Of 235 patients screened, 52 were randomized. The mean length of Barrett's esophagus was 3.1 cm in the MPEC group vs. 4.0 cm in the APC group (p = 0.03). Otherwise, the treatment groups were similar with regard to baseline characteristics. The mean number of treatment sessions required for endoscopic ablation was 2.9 for MPEC vs. 3.8 for APC (p = 0.04) in an intention-to-treat analysis (p = 0.249, after adjustment for the difference in length of Barrett's esophagus). The proportion of patients in which ablation was endoscopically achieved proximal to the gastroesophageal junction was 88% for the MPEC group vs. 81% for the APC group (p = 0.68) and histologically achieved in 81% for MPEC vs. 65% for APC (p = 0.21). The mean time required for the first treatment session was 6 minutes with MPEC vs. 10 minutes with APC (p = 0.01) in per protocol analysis. There was no serious adverse event, but transient moderate to severe upper-GI symptoms occurred after MPEC in 8% vs. 13% after APC (p = 0.64). Conclusions Although there were no statistically significant differences, ablation of Barrett's esophagus with pantoprazole and MPEC required numerically fewer treatment sessions, and endoscopic and histologic ablation was achieved in a greater proportion of patients compared with treatment with pantoprazole and APC.     

内镜下氩离子凝固术联合质子泵抑制剂治疗疣状胃炎临床观察

目的探讨内镜下氩离子凝固术（APC）联合质子泵抑制剂治疗疣状胃炎的疗效。方法 88例疣状胃炎患者随机分为治疗组和对照组,治疗组内镜下氩离子凝固术联合质子泵抑制剂（奥美拉唑）治疗,对照组应用质子泵抑制剂（奥美拉唑）治疗,疗程为4周,对两组幽门螺杆菌（Helicobacter pylori,Hp）阳性者,同时应用阿莫西林、甲硝唑进行治疗,疗程为7d。4周后复查胃镜,判定疗效。结果治疗组临床症状改善和内镜病灶消失的有效率显著高于对照组（P〈0.01）,Hp根除率两组无统计学差异（P〉0.05）。结论 APC术联合质子泵抑制剂治疗疣状胃炎疗效确切、安全可靠,临床值得推广。     

Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy

OBJECTIVES: Barrett's metaplasia is an acquired condition resulting from longstanding gastroesophageal reflux disease. Approximately 10% of esophagitis patients develop Barrett's esophagus. There is increasing evidence that duodenogastroesophageal reflux plays a role in the progression of disease. We further analyzed the correlation of acid and biliary reflux with reflux esophagitis and Barrett's esophagus and tested the effects of proton pump inhibitor therapy. METHODS: Patients with either reflux esophagitis (group 1) or Barrett's esophagus (group 2) prospectively underwent simultaneous 24-h esophageal pH and bile reflux testing without any therapy affecting acid secretion or GI motility. A total of 16 patients in group 1 and 18 patients in group 2 were tested again under proton pump inhibitor therapy. RESULTS: Acid and bile exposure were significantly increased in Barrett's patients (n = 23) compared to 20 esophagitis patients (median percentage of time that pH was <4 was 24.6% vs 12.4%, p = 0.01, median percentage of time that bilirubin absorbance was >0.2 was 34.7% vs 12.8%, p < 0.05). During therapy, both acid and bile reflux decreased significantly in both groups. Median percentage of time that pH was <4 and bilirubin absorbance was >0.2 before and during therapy was 18.2%/2.3% and 29.8%/0.7% (p = 0.001 and p = 0.001) in Barrett's esophagus patients versus 14.5%/3.6% and 21.5%/0.9% (p = 0.002 and p = 0.011) in esophagitis patients. There was no significant difference between the groups. In two esophagitis patients, bile reflux increased during therapy. CONCLUSIONS: There is a good correlation of the duration of esophageal exposure to acid and bile with the severity of pathological change in the esophagus. Both acid and bile reflux is significantly suppressed by proton pump inhibitor therapy with exceptions among individual esophagitis patients. The prolonged simultaneous attack of bile and acid may play a key role in the development of Barrett's metaplasia.     

Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett's esophagus after antireflux surgery

BACKGROUND: Argon plasma coagulation is one of several techniques used to ablate Barrett's esophagus. This study assessed the efficacy and safety of argon plasma coagulation in the ablation of Barrett's esophagus in patients who have undergone antireflux surgery. METHODS: A total of 40 patients with Barrett's esophagus who had undergone a fundoplication were entered into a prospective, randomized, unblinded study comparing argon plasma coagulation with endoscopic surveillance. Treatment was repeated until either no Barrett's epithelium remained or a maximum of 6 treatment sessions. RESULTS: One month after the final treatment, complete ablation was achieved in 12 patients. In the remaining 8, a reduction of over 95% was observed. One patient died at 9 months of an unrelated cause. At 1 year, one patient with residual Barrett's epithelium regressed completely, while relapse of Barrett's esophagus was seen in another because of fundoplication failure. Buried glands were observed in 35% patients at 1 month, but only 5% at 1 year. Dysplasia was never seen. In the surveillance group, partial regression was observed in 11 patients, and, in 3 with short-segment Barrett's esophagus, regression was complete. The length of Barrett's esophagus increased in two patients. Two had low-grade dysplasia initially, but this was not evident at 1 year. Overall, complete ablation was achieved in 12 of 19 (63%) patients in the ablation group and 3 of 20 (15%) in the surveillance group (p<0.01). CONCLUSIONS: Argon plasma coagulation of Barrett's esophagus is safe and effective. The effects are durable, and buried glands may resolve with time. Long-term follow-up is required to assess the impact of argon plasma coagulation on cancer risk.     

High power setting argon plasma coagulation for the eradication of Barrett's esophagus

OBJECTIVE: The term Barrett's esophagus refers to a premalignant condition that is characterized by the replacement of the esophageal squamous mucosa by a columnar-lined one. Preliminary studies have demonstrated reversal of Barrett's mucosa after endoscopic coagulation with different techniques associated with acid inhibition. However, most of these studies have shown that residual Barrett's glands are found underneath the new squamous epithelium in up to 40% of patients. The goal of our study is to verify whether complete restoration of Barrett's mucosa can be achieved by the combination of high power setting argon plasma coagulation and omeprazole. METHODS: A total of 33 patients (mean age: 55.2 yr, range: 21-84 yr; 21 men and 12 women) with histologically demonstrated Barrett's esophagus (mean length: 4.05 cm, range: 0.5-7 cm) were treated. Fourteen cases presented with low-grade dysplasia and one with high-grade dysplasia. All of the extent, or until a maximum of 4 cm, of the Barrett's mucosa was cauterized in each session using argon beam coagulation at a power setting of 65-70 W. All patients received 60 mg omeprazole during the treatment period. RESULTS: Complete restoration of squamous mucosa was obtained in all 33 cases after a mean of 1.96 sessions (range, 1-4). Endoscopic results were histologically confirmed. Nineteen (57.5%) patients experienced moderate to severe chest pain and odyno-dysphagia lasting for 3-10 days after the procedure. Five of these cases experienced high fever and a small volume of pleural effusion, and three patients developed esophageal strictures that needed to be dilated. Another patient developed pneumomediastinum and subcutaneous emphysema without evidences of perforation. After a mean follow-up of 10.6 months there was one endoscopic, as well as histological, recurrence of Barrett's mucosa in a patient with an ineffective laparoscopic fundoplication. CONCLUSIONS: High power setting argon plasma coagulation combined with intensive acid suppression is an effective treatment for the total endoscopic ablation of Barrett's esophagus, at least in the short term. Long-term follow-up of treated patients in whom gastroesophageal reflux is surgically or medically alleviated seems mandatory before drawing definitive conclusions about this therapy.     

Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole

BACKGROUND: Barrett's esophagus is a premalignant condition induced by gastroesophageal reflux. The aim of this prospective study was to assess the efficacy of argon plasma coagulation in combination with high-dose omeprazole therapy to ablate nondysplastic Barrett's epithelium. METHODS: In 73 patients with histologically confirmed Barrett's epithelium, argon plasma coagulation was used in combination with maximal acid suppression (omeprazole 40 mg three times a day). Histologic and endoscopic changes were evaluated at 6- and 12-month intervals. RESULTS: In 69 of 70 patients (98.6%) complete squamous regeneration was achieved after a median of 2 argon plasma coagulation sessions (range 1 to 5). During a median follow-up of 12 months (range 2 to 51 months) there has been no relapse or evidence of the development of dysplasia under continuous acid suppression. Three patients (4.3%) developed a mild stricture of the distal esophagus that resolved after a single session of bougie dilation. CONCLUSIONS: In our experience, argon plasma coagulation in combination with high-dose omeprazole treatment is an effective and safe technique for complete ablation of nondysplastic Barrett's epithelium. Restoration of squamous mucosa after argon plasma coagulation appears to be long-lasting.     

Endoscopic ablation of Barrett''s esophagus using argon plasma coagulation: a prospective study after fundoplication

The aim of the prospective clinical study presented here is to test the effectiveness of a multimode approach consisting of argon plasma coagulation combined with laparoscopic fundoplication in the management of Barrett's esophagus. Argon plasma coagulation was performed in 19 patients with Barrett's esophagus who had previously undergone surgical antireflux treatment. The mean follow-up time was 17 months, ranging between 6 and 27 months. Squamous epithelium was completely restored in all patients. In 68.4% of cases two sessions were required. The most frequent complications were chest discomfort and retrosternal pain. In 11 patients the symptoms lasted 3 days and in six cases persisted for a longer period, requiring analgesic medication. Short-term dysphagia and odynophagia were observed in four patients.